December 22, 2022 Spotlight - Biotech tries everything it can in Nash The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.
February 19, 2019 Inventiva’s fibrosis flop hits Nash hopes A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.
